Brief: Waters And Bd's Biosciences & Diagnostic Solutions Business To Combine, Creating A Life Science And Diagnostics Leader Focused On Regulated, High-Volume Testing

Waters

14/07/2025 12:14

Becton Dickinson and Co BDX.N:

WATERS AND BD'S BIOSCIENCES & DIAGNOSTIC SOLUTIONS BUSINESS TO COMBINE, CREATING A LIFE SCIENCE AND DIAGNOSTICS LEADER FOCUSED ON REGULATED, HIGH-VOLUME TESTING

WATERS CORP - COMBINED COMPANY EXPECTED 2025 SALES OF $6.5 BILLION

WATERS CORP - BD TO RECEIVE $4 BILLION CASH DISTRIBUTION PRIOR TO COMPLETION OF THE COMBINATION

WATERS CORP - DEAL EXPECTED TO BE ACCRETIVE TO EPS IN FIRST YEAR

WATERS CORP - ANTICIPATE $345 MILLION EBITDA SYNERGIES BY 2030

WATERS CORP - BD'S SHAREHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 39.2% OF COMBINED CO

WATERS CORP - UDIT BATRA TO LEAD NEW ENTITY POST-DEAL

WATERS CORP - DEAL STRUCTURED AS A TAX-EFFICIENT REVERSE MORRIS TRUST DEAL VALUED AT ABOUT $17.5 BILLION

WATERS CORP - AMOL CHAUBAL TO SERVE AS SVP AND CHIEF FINANCIAL OFFICER OF NEW ENTITY

WATERS CORP - NEW CO TO OPERATE UNDER WATERS NAME & RETAIN LISTING ON NYSE UNDER TICKER SYMBOL WAT

Source text: ID:nPn8rNx4Ha

Further company coverage: BDX.N